Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma

doi:10.5306/wjco.v10.i3.149

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8850)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

412

WORD

297

HTML

4595

Figures (1-5)

266

Tables (1-3)

207

Sum=5777

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

625

Download

859

Sum=1484

Publishing Process of This Article

Item

Count

Browse

685

Download

904

Sum=1589

Mar 24, 2019 (publication date) through Sep 9, 2024

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Oncol. Mar 24, 2019; 10(3): 149-160
Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.149

Full Size Figure Download Figure

Figure 3 Biomarker analysis plan to dissect mechanism of action of hypoxia inducible factor-1αlpha inhibitors. HIF-1α: Hypoxia inducible factor-1αlpha; HIF2: Hypoxia inducible factor 2; HIF-1α mRNA: Hypoxia inducible factor 1-alpha messenger ribonucleic acid; EPO: Erythropoietin; VEGF: Vascular epidermal growth factor; IHC: Immunohistochemistry; vWF: Von willebrand factor; CD34: Cluster of differentiation 34; PR: Partial response; DCE-MRI: Dynamic contrast-enhanced magnetic resonance imaging; RECIST: Response evaluation criteria in solid tumors.

Citation: Wu J, Contratto M, Shanbhogue KP, Manji GA, O’Neil BH, Noonan A, Tudor R, Lee R. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma. World J Clin Oncol 2019; 10(3): 149-160
URL: https://www.wjgnet.com/2218-4333/full/v10/i3/149.htm
DOI: https://dx.doi.org/10.5306/wjco.v10.i3.149